“The combination of this ubiquitous cell source and the reprogramming technology is unique and powerful for realization of personalized medicine to cure diseases.”
(Regina Grillari)
Phoenestra is changing current standards of tissue sourcing by using urine as primary cell source for the generation of induced pluripotent stem cell lines from HLA typed donors for the establishment of novel allogeneic or autologous cell based therapies in the field of personalized medicines.

Urine as universal cell source makes the difference

Phoenestra GmbH aims at the establishment of human integration-free, xeno-free induced pluripotent stem cell lines (iPSCs) from urine-derived cells. In contrast to other cell sources such as skin or blood for reprogramming, urine can be collected non-invasively, is universal without limitation and can be easily transported across borders after cryopreservation. Any consenting individual is a potential donor, as no ethical concerns exist. Moreover, urine cells might bear less spontaneous mutations, as these exfoliated cells have not been exposed to e.g. UV irradiation such as skin-derived fibroblasts. Additionally, cells can be grown from urine sediments without further tissue disaggregation or any manipulation, which is an important point when thinking of regulatory requirements during the development of cell-based therapies.

All these advantages make urine a valuable starting material for the generation of iPSCs for the development of novel therapeutic strategies.

Phoenestra is setting up a biobank, the urine cell recovery agency (UCRA) for the storage of urine sediments (i) from HLA-typed donors and (ii) from patients suffering from specific diseases. Additionally, Phoenestra collects and stores urine sediments upon customer requests. Using these urine sediments iPSCs will be generated under GMP conditions. These cells are then the basis for the establishment of novel allogeneic or autologous therapeutic strategies from the differentiated products thereof. All our iPS cell lines will be characterized for expression of typical pluripotency markers as well as sterility, identity and freedom from human pathogenic viruses as well as residual reprogramming vectors. Special emphasis will be put on the karyotype stability of the established iPSCs.


„All services are offered as milestone based projects including stop and go decisions and will be discussed in detail with our partners“
(Otto Kanzler)

Generation of donor-specific Induced Pluripotent Stem (iPS) Cells

Phoenestra has developed protocols for the isolation and expansion of cells isolated from fresh urine as well as frozen urine sediments. Using these urine sediments Phoenestra establishes iPS cell lines, which will be characterized in detail for expression of cell-type specific markers and functions as well as for identity, sterility, karyotype stability as well as freedom from human pathogenic viruses and residual reprogramming vectors. The generation of iPSCs can be performed under GMP or under non- GMP conditions.

Development of differentiation protocols

Phoenestra has developed protocols for the differentiation of iPSCs towards neurons, cardiomyocytes and hepatocyte like cells. Moreover, the establishment of differentiation protocols towards other cells is offered to our customers.

Please contact us for quotes on cells and services via